Nanotechnology Drug Delivery Market (Technology: Nanocrystals, Nanoparticles, Liposomes, Micelles, Nanotubes, and Others; and Application: Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective, and Others)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Nanotechnology Drug Delivery market size is expected to hit around USD 150.8 billion by 2030 from valued at USD 80.1 billion in 2021 and growing at a CAGR of 10.9% from 2022 to 2030.

Nanotechnology Drug Delivery Market: Overview

  • The role of technology in the delivery of medicine assures revolutionary advances in measuring the size of the particles in nanometer ranges
  • One important and active application area of nanotechnology drug delivery systems (DDS) is to transport drugs to the final location of therapeutic intervention within the body. Various organic and inorganic nanomaterials have been utilized for DDS applications.
  • The term nano pharmaceuticals (nano drugs) cover different nano-based DDS that can be used to encapsulate drugs for better targeting than with conventional drugs
  • The most common nanomaterials utilized for DDS include nanocrystals, liposome, protein-conjugate, dendrimers, and nanoparticles

Report Scope of the Nanotechnology Drug Delivery Market

Report Coverage

Details

Market Size

USD 150.8 Billion by 2030

Growth Rate

CAGR of 10.9% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year

2021

Forecast Period

2022 to 2030

Segments Covered

 Technology, Application And Region

Companies Mentioned

 AbbVie Inc. (AbbVie), Amgen Inc., Aquanova AG, Bayer AG, Camarus AB, Celgene Corporation, Cytimmune Sciences, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc. Nanobiotix, NanoCarrier Co, Ltd, NanOlogy LLC, Novartis AG, Pfizer Inc. (Pfizer), Roche Holding AG (Roche), Sanofi SA, Selecta Biosciences Inc., Starpharma Holdings Limited, Taiwan Liposome Co. Tarveda Therapeutics

       Developing Potential of Existing Pharmaceutical Drugs: Key Driver

  • The global pharmaceutical industry has been developing compounds for over a century. However, several of these never got to the market. Acceptance of new drug formulations is expensive and slow, taking up to 15 years to obtain accreditation of new drug formulas with no guarantee of success.
  • Antineoplastic agents are highly effective in cancer treatment; however, it leads to chronic side effects due to cytotoxic properties and lack of target specificity. Hence, pharmaceutical companies are developing innovative drug delivery systems to increase target specificity for the cytotoxic drugs that are already present in the market.
  • New drug delivery compounds are likely to extend the product and patent lifecycles of drugs, enabling the creation of new chemical entities (NCEs) via reformulation of existing and/or orphaned compounds, and subsequent creation of value for shareholders and consumers
  • Therefore, renewing the product lifecycle of existing drugs is expected to boost market growth during the forecast period

Clinical Advantages of Nanotechnology in Drug Delivery: Major Driver

  • Benefits of nanotechnology-based drug delivery systems for both doctors and patients are lower drug toxicity, more specific targeting, and reduced cost of treatment
  • Presently, several drug entities fail clinical trials because the compound is incapable to reach the targeted site without exhibiting any side effects. Delivery of a compound to specific target site is one of the most integral parts of any treatment ranging from infections to cancer.
  • The overall drug consumption and side effects can be lowered significantly using nanotechnology drug delivery. The highly selective approach reduces the side effects and cost as well.
  • These factors are likely to propel the global nanotechnology drug delivery market during the forecast period

Some of the prominent players in the Nanotechnology Drug Delivery Market include:

• AbbVie Inc. (AbbVie)

• Amgen Inc.

• Aquanova AG

• Bayer AG

• Camarus AB

• Celgene Corporation

• Cytimmune Sciences

• GlaxoSmithKline PLC

• Johnson & Johnson

• Merck & Co., Inc.

• Nanobiotix

• NanoCarrier Co, Ltd

• NanOlogy LLC

• Novartis AG

• Pfizer Inc. (Pfizer)

• Roche Holding AG (Roche)

• Sanofi SA

• Selecta Biosciences Inc.

• Starpharma Holdings Limited

• Taiwan Liposome Co.

• Tarveda Therapeutics

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Nanotechnology Drug Delivery market

  • Technology
    • Nanocrystals
    • Nanoparticles
      • Dendrimers
      • Gold Nanoparticles
      • Fullerenes
    • Liposomes
    • Micelles
    • Nanotubes
    • Others
  • Application
    • Neurology
    • Oncology
    • Cardiovascular/Physiology
    • Anti-inflammatory/Immunology
    • Anti-infective
    • Others (Hematology, Ophthalmology, etc.)

By Regional Outlook

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Nanotechnology Drug Delivery industry analysis from 2022 to 2030 to identify the prevailing Nanotechnology Drug Delivery industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Nanotechnology Drug Delivery industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Nanotechnology Drug Delivery industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:7055
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000